Peripheral Neuropathy Clinical Trials

This study will see if an investigational drug called NYX-2925 can reduce the nerve pain in the legs and feet associated with painful diabetic peripheral neuropathy.

We are currently seeking volunteers with either Type 1 or Type 2 diabetes who experience moderate to severe painful diabetic neuropathy. This is a study of a new investigational injectable medication that may help to slow down, stop, or even reverse the progression of neuropathy. Eligible patients will be determined ...

Do you have Diabetic Peripheral Neuropathy?

The purpose of this study is to evaluate investigational tapentadol extended release (ER) when compared to placebo. Placebo is a dummy pill with no active drug, but looks like the real drug. Tapentadol is an opiod (narcotic) drug. Tapentadol immediate release (IR) has already been approved in does of 50, ...

Endeavor Clincial Trials is seeking volunteers to participate in a Diabetic Peripheral Neuropathy (DPN) research study.

The objectives of the MEDIAN study are to evaluate the short-term and long-term safety and nutritional benefits of Metanx® versus placebo in subjects with mild to moderate diabetic peripheral neuropathy (DPN). Short-term effects will be evaluated during the first 16 weeks of treatment, and long-term effects will be evaluated over ...

Suffering from Diabetic Neuropathy? If you suffer from Diabetic Peripheral Neuropathy, also known as DPN, you may be interested in learning more about a research study of an investigational medication being conducted locally.

This study will look at factors that combine to cause muscle, joint and movement deterioration in patients with type 2 diabetes. This study will last 3 years. There are up to 8 physical therapy visits. There will be completion of questionnaires, foot x-ray, motion analysis, MRI scan and CT scan ...

This is a randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study to assess the efficacy and safety of NYX-2925 in subjects with neuropathic pain associated with diabetic peripheral neuropathy. The study will be a 6 to 9-week study, including a 1-to 4-week (dependent on duration of washout period) Screening Period, followed by ...

Primary objective: To evaluate the efficacy of multiple dose levels of NYX-2925 versus placebo in treating the neuropathic pain associated with diabetic peripheral neuropathy